Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission
概览
- 阶段
- 2 期
- 干预措施
- Azacitidine
- 疾病 / 适应症
- Acute Myeloid Leukemia in Remission
- 发起方
- M.D. Anderson Cancer Center
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Relapse-free survival (RFS)
- 状态
- 进行中（未招募）
- 最后更新
- 3个月前
概览
简要总结
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
详细描述
PRIMARY OBJECTIVES: I. To assess relapse-free survival (RFS) of patients (pts) with acute myeloid leukemia (AML) treated with 5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission. SECONDARY OBJECTIVES: I. To assess modified RFS of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy. II. To assess overall survival (OS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy. III. To assess event-free survival (EFS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy. IV. To assess the duration of remission (CRd) of pts with AML treated 5-azacytidine combined with venetoclax as maintenance therapy. V. To assess toxicity and safety of 5-azacytidine combined with venetoclax as maintenance therapy in pts with AML. VI. To assess the effects of 5-azacytidine combined with venetoclax on dynamics of minimal residual disease (MRD) and their relationship to outcomes. OUTLINE: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 1 hour daily on days 1-5, and venetoclax orally (PO) daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 6-12 months thereafter.
研究者
入排标准
入选标准
- •Patients aged \>/= 18 years AML who have achieved their FIRST CR or CRi and are not immediately candidates for allogeneic stem cell transplant.
- •Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be enrolled in COHORT
- •Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine (LDAC) or hypomethylating agent (HMA)-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be treated on COHORT
- •For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement.
- •ECOG performance status of \< or = 3
- •Adequate organ function as follows:
- •Serum total bilirubin \< or = to 1.5 X the Upper Limit of Normal (ULN)
- •Serum creatinine \< or = to 2.5 x ULN
- •Adequate BM reserve:
- •Absolute neutrophil count (ANC) \> 0.5 x k/uL
排除标准
- •Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by FAB classification based on morphology, immunophenotype, molecular, or cytogenetic s studies.
- •Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor.
- •Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients with active CNS (central nervous system) disease.
- •Patients with documented hypersensitivity to any components of the study program.
- •Females who are pregnant or lactating or intending to become pregnant during the study.
- •Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment.
- •Patient should be removed from current trial if they wish to participate and get treatment on another trial.
研究组 & 干预措施
Treatment (azacytidine, venetoclax)
Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
干预措施: Azacitidine
Treatment (azacytidine, venetoclax)
Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
干预措施: Venetoclax
结局指标
主要结局
Relapse-free survival (RFS)
时间窗: From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years
The study will be continuously monitored for the primary endpoint, RFS, using the method of Thall, Wooten, and Tannir (2005). Will also summarize the posterior distribution of lambda-E (i.e., median RFS) assuming posterior mean and 95% credible interval.
次要结局
- Complete remission duration (CRd)(Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years)
- Incidence of toxicity(Up to 10 years)
- Modified RFS(Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years)
- Overall survival (OS)(From the start of study treatment until date of death due to any cause, assessed for up to 10 years)
- Event free survival (EFS)(From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years)